Cargando…
Waldenström macroglobulinemia: biology, genetics, and therapy
Waldenström macroglobulinemia (WM) is a distinct clinicopathologic entity characterized by the presence of a lymphoplasmacytic lymphoma, a non-Hodgkin lymphoma, and IgM monoclonal gammopathy. WM is an indolent, uncommon malignancy mostly affecting the elderly. Patient outcomes have modestly improved...
Autores principales: | Paludo, Jonas, Ansell, Stephen M |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6467336/ https://www.ncbi.nlm.nih.gov/pubmed/31360080 http://dx.doi.org/10.2147/BLCTT.S84157 |
Ejemplares similares
-
Coming of Age for BTK Inhibitor Therapy: A Review of Zanubrutinib in Waldenström Macroglobulinemia
por: Muñoz, Javier, et al.
Publicado: (2022) -
Increased glutathione utilization augments tumor cell proliferation in Waldenstrom Macroglobulinemia
por: Jalali, Shahrzad, et al.
Publicado: (2020) -
Waldenstrom’s Macroglobulinemia: An Update
por: Mazzucchelli, Maddalena, et al.
Publicado: (2018) -
Epigenetic modifications as key regulators of Waldenstrom's Macroglobulinemia biology
por: Sacco, Antonio, et al.
Publicado: (2010) -
Waldenstrom macroglobulinemia: prognosis and management
por: Oza, A, et al.
Publicado: (2015)